Full history for every metric is available with a Kvantra account
Rubius Therapeutics, Inc. (RUBY)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -178 | -155 | |||||
| Net profit | $m | -44 | -89 | -160 | -162 | -189 | -231 | -234 |
| EPS reported | $ | -2.56 | -2.59 | |||||
| Operating cashflow per share | $ | -1.66 | -1.66 | |||||
| Capex per share | $ | 0.06 | 0.06 | |||||
| FCF per share | $ | -1.72 | -1.72 | |||||
| Free cash flow | $m | -155 | -155 | |||||
| Net debt | $m | -18 | -19 | |||||
| Book value equity | $m | 15 | 15 | |||||
| Book value per share | $ | 0.17 | 0.17 | |||||
| Number of shares | m | 90.31 | 90.43 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.04 | 0.34 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.10 | -0.03 | |||||
| EV/EBITDA LTM | x | -0.01 | 0.08 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -1460.8% | -4485.0% | |||||
| FCF Yield | % | -983.62% | -3015.6% | |||||
| Quality | ||||||||
| ROE | % | -1525.8% | -238.11% | |||||
| ROIC | % | -1099.4% | -1099.4% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -141.31 | -141.31 | |||||
| Net Debt/EBITDA | x | 0.08 | 0.08 | |||||
| EBIT/Net interest | x | -46.19 | -46.19 | |||||
| Net debt/market cap | % | -112.86% | -367.33% | |||||
| Net debt/Equity | x | -1.18 | -1.25 | |||||
| Gross debt/equity | x | 0.07 | 0.07 | |||||
Company overview
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Rubius Therapeutics, Inc. (RUBY)
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free